Translarna: EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine

View source ↗

Summary

The EMA confirms that it will not renew Translarna's authorization for Duchenne muscular dystrophy after a re-examination, because effectiveness could not be co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Translarna (ataluren)

Snippet

Re-examination concludes effectiveness has not been confirmed